Trial Profile
Zonisamide for Weight Reduction in Obese Adults.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 14 Aug 2013 Results published in JAMA: the Journal of the American Medical Association.
- 12 Nov 2012 Primary endpoint 'Bodyweight-reduction' has been met for 400 mg/day dosage, according to results in the Archives of Internal Medicine.
- 12 Nov 2012 Results published in the Archives of Internal Medicine.